Pfizer UK removes sales incentives for anti-infectives
28 September 2019
Pfizer UK has changed how it incentivises its anti-infectives field-force under the drug giant’s commitment to the fight against antimicrobial resistance (AMR).
All sales have been ‘de-linked’ from its anti-infectives (AI) field-force incentives, with the focus now on measuring management-based objectives (MBOs) centering on generating access to medicines and promoting the appropriate use of antibiotics.
Further reading: PharmaTimes
Author(s): Pharmatimes
Effective Surveillance
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
